SecBot SecBot

ATRA

Atara Biotherapeutics, Inc.
Nasdaq· Biological Products, (No Diagnostic Substances)· Inc. DE· CIK 0001604464 Biotech & Drug Discovery
$6.40 −1.30 (−16.88%)
Nov 16 4:00 PM ET · prev $7.70
Market cap
$80.8M
Micro cap
Median target
$13.00
+103% · range $10.00–18.00
1 year
−51.1%
from $13.10 · Nov 17
30 days
−28.6%
from $8.96
52-week range
$4.18–18.09
−65% from high · low Feb 20
Avg volume 20D
22.8K
shares / day
Short interest
296.7K
≈3.0% of shares · −15.3%
Days to cover
13.4
at average volume
Insider net
+$2.4M
2 buyers · 3 sellers · 12 mo
New fund stakes
0
Q3 2026 13F · 0 exits
Filing reports
11
analyzed by SecBot
SecBot read BEARISH 2 reports · 90 days
Balance 1 bearish · 0 bullish · 1 neutral oldest → newest, height = score
Avg score ·High conf. 2/2 ·Next FDA decision date, Mar 31, 2027

Price

Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).

Signal stack

Where each data set points today.

  • InsidersMIXED

    2 insiders bought $5.7M at an average $9.39. 3 insiders sold $3.3M. Price is 32% below their cost.

  • InstitutionsMIXED

    Q3 2026: 4 added (0 new), 3 trimmed or exited.

  • Short sellersCOVERING

    Short interest −15.3% to 296.7K shares. 13.4 days to cover, ≈3.0% of shares.

  • TrendDOWNTREND

    28% below its 50-day average.

Who's buying

13F· Q3 2026
0
new positions
0
exits
FundMoveSharesValue
UBS Group AGDOUBLED20,756$176.4K
Vanguard Global Advisers, LLCDOUBLED4,654$39.6K
JONES FINANCIAL COMPANIES LLLPTRIM303$2.7K
BARCLAYS PLCTRIM214$1.8K
CITIGROUP INCNEAR_EXIT1$9.00
Point72 Asset Management, L.P.DOUBLED687,718$7.9M
MACKENZIE FINANCIAL CORPTRIM233,249$2.7M
VANGUARD FIDUCIARY TRUST COADD43,036$494.1K

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

Last action May 2026
12-month targets · 3 analysts

Price is below the lowest target. Median implies +103%.Targets as of Nov 17, 2026.

Recent actions
DateFirmActionRating
May 18, 2026Freedom Broker
UPGRADE
UPGRADEHold
May 8, 2026Canaccord Genuity
UPGRADE
UPGRADEBuy
Jan 21, 2026Freedom Broker
DOWNGRADE
DOWNGRADESell
Jan 13, 2026Canaccord Genuity
DOWNGRADE
DOWNGRADEHold
Dec 19, 2025Canaccord Genuity
MAINTAIN
MAINTAINBuy
Mar 11, 2025Canaccord Genuity
MAINTAIN
MAINTAINBuy

Insider ledger

Form 4
$5.7M
bought · 2 insiders
$3.3M
sold · 3 insiders
−31.9%
vs their $9.39 cost
DateInsiderTypeValue
Sep 4, 2026
Cherry Brian N
Director
Sep 4, 2026
BUY$1000.0K
Aug 17, 2026
Nguyen AnhCo
President and CEO
Aug 17, 2026
SELL$40.9K
Jul 22, 2026
Redmile Group, LLC
Director
Jul 22, 2026
EXERCISE195,211 sh
Jul 22, 2026
Redmile Group, LLC
Director
Jul 22, 2026
EXERCISE55,387 sh
Jul 22, 2026
Redmile Group, LLC
Director
Jul 22, 2026
TAX W/H60 sh
Jul 22, 2026
Redmile Group, LLC
Director
Jul 22, 2026
EXERCISE101,089 sh
Jul 22, 2026
Redmile Group, LLC
Director
Jul 22, 2026
EXERCISE38,735 sh
Jun 11, 2026
Cherry Brian N
Director
Jun 11, 2026
AWARD24,000 sh

Earnings setup

Estimates

Revision history: 🔒 Fresh data, subscribers only

PeriodEPS est.Range30D rev.Revenue
Current Q🔒 Fresh data, subscribers only
Next Q🔒 Fresh data, subscribers only
Current FY🔒 Fresh data, subscribers only
Next FY🔒 Fresh data, subscribers only

Washington

Corporate Lobbying

6 lobbying filings and 0 bills this company lobbies on, with spend, stage and how each bill touches it, are for subscribers.

Subscribe for Full Access

Short side

FINRA· Oct 30, 2026
296,651
shares short
-15.3%
vs prior settlement
13.4
days to cover
≈3.0%
of shares outstanding
Recent activity
The latest filings, insider trades, analyst actions, press and options flow, newest first.
Nov 10, 2026 SEC
Atara Biotherapeutics filed a replacement S-3 shelf registration statement covering up to $200M in securities…
S-3 · Impact 5/10
Nov 10, 2026 SEC
Atara reported Q3 2026 revenue of $1.2M (down 65% YoY from $3.5M, due to a one-time prior-year clinical inventory…
8-K · Impact 5/10
Oct 29, 2026 Earnings calendar
ATRA Q3 2026 Earnings Scheduled · 2026-10-29
Sep 30, 2026 Inst.
UBS Group AG · DOUBLED
20,756 shares ($176.4K)
Sep 30, 2026 Inst.
Vanguard Global Advisers, LLC · DOUBLED
4,654 shares ($39.6K)
Sep 4, 2026 Insider
Cherry Brian N bought 104,166 shares
Director @ $9.60 ($1000.0K)
Aug 17, 2026 Insider
Nguyen AnhCo sold 5,062 shares
President and CEO @ $8.08 ($40.9K)
Jul 22, 2026 Insider
Redmile Group, LLC acquired via exercise 195,211 shares
Director
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
1 drug tracked · Drug pipeline →
Upcoming
Recent

SecBot reports

11 filings · 0 bullish · 1 bearish · 2 mixed · 8 neutral
All ATRA filing & press-release reports (11)